ArticleESMO open2025

Letter re: Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2.

Arif Hakan ÖnderPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.